Advanced Micro Devices
AMD
NVIDIA
NVDA
Tesla
TSLA
4
Alphabet-C
GOOG
5
Alphabet-A
GOOGL
US Stock MarketDetailed Quotes
AKBA Akebia Therapeutics
- 2.450
- -0.030-1.21%
Close May 14 16:00 ET
- 2.544
- +0.094+3.84%
Post 20:01 ET
643.46MMarket Cap-11.67P/E (TTM)
2.540High2.425Low3.66MVolume2.480Open2.480Pre Close9.11MTurnover1.43%Turnover RatioLossP/E (Static)262.64MShares2.90052wk High26.06P/B629.38MFloat Cap0.80052wk Low--Dividend TTM256.89MShs Float31.000Historical High--Div YieldTTM4.64%Amplitude0.241Historical Low2.486Avg Price1Lot Size
Market Insights
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Akebia Therapeutics Stock Forum
•Revenues: Total revenues were $57.3 million in the first quarter of 2025 as compared to $32.6 million in the first quarter of 2024, driven by initial sales of Vafseo in the U.S. and an increase in sales of Auryxia.
▪Vafseo net product revenues were $12.0 million in the first quarter of 2025. Vafseo was launched into the U.S. market in the first quarter of 2025.
▪Auryxia net product revenues were $43.8 million in the first quarter...
Major Win for Akebia: EMA Committee Recommends Novel Dual-Action Kidney Disease Treatment
Akebia Therapeutics: Ec Will Review Chmp Recommendation, Final Decision Expected in About Two Months
No comment yet